Pharma IQ | 10/13/2010
Mandar Kodgule, Head of Intellectual Property and Strategic Planning at Wockhardt, answers this question as well as offering the top five strategic considerations to sustain a healthy polymorph patent portfolio and to create polymorphic wealth. In this interview with Helen Winsor from Pharma IQ, he also touches upon how the regulatory landscape is changing and what impact it is having on enforceability of polymorph patents. Kodgule also addresses the issue of excessive innovation...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More